« What Should Non-Chemists Know About Medicinal Chemistry, Anyway? |
| A Database of Side Effects »
January 20, 2010
Honesty, Of A Sort
Chris Viehbacher, CEO of Sanofi-Aventis, gave a speech out at the recent J. P. Morgan healthcare fiesta in San Francisco. He spoke about how nasty the last ten years have been for the industry, calling it a "lost decade", but one particular item really caught my eye (emphasis mine):
". . .for the most part people have zero expectations of Sanofi-Aventis research and development,” he said. “We’ve basically cleared out a lot of bad news, and if anything comes along it should be good news.”
Well, that's one way to do it. I wonder if the performance reviews and yearly goal-setting forms over there read the same way?
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- Phenotypic Assays in Cancer Drug Discovery
- Neratinib Comes Through For Puma
- How Many Biopharma Employees Would Rather Be Working Somewhere Else?
- The Broad Gets $650 Million For Psychiatric Research
- Put Them in Cells and Find Out
- The Hep C Field Gets Nastier By the Minute
- Allergan Twists and Turns
- Chemistry Class For the "Food Babe"?